查看購物車
  • English
  • Japanese
  • Korean
全球體液分析市場：依產品、技術、類型、體液類型、應用、最終用戶和地區分類－預測至2031年
市場調查報告書
商品編碼
2086832

全球體液分析市場：依產品、技術、類型、體液類型、應用、最終用戶和地區分類－預測至2031年

Body Fluid Analysis Market by Product (Consumables, Instruments), Technology (Immunoassay, PCR, Flow Cytometry), Fluid Type (CSF, Pleural, Synovial, Peritoneal, Semen), Application (Clinical Diagnostics, Forensic, Research) - Global Forecast to 2031
出版日期: | 出版商: MarketsandMarkets | 英文 356 Pages | 訂單完成後即時交付

價格

預計體液分析市場規模將從 2026 年的 26.2 億美元成長到 2031 年的 36.5 億美元，複合年成長率為 6.9%。

阿茲海默症和帕金森氏症等神經系統疾病的日益普遍推動了對腦脊髓液 (CSF) 生物標記檢測的需求，而肌肉骨骼疾病和人工關節周圍感染疾病的發病率不斷上升，擴大了滑液分析的應用。

調查範圍
調查期 2026-2031
基準年 2025
預測期 2026-2031
計算單位 金額（10億美元）
部分 按產品、技術、類型、流體類型、應用、最終用戶和地區分類。
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東和非洲

此外，自動化分析儀、流式細胞技術、免疫檢測和分子診斷技術的進步提高了專業體液檢測的準確性、效率和標準化程度。這些創新使醫療專業人員能夠做出更準確的診斷和治療決策，最終促進了市場成長。

體液分析市場-IMG1

“在預測期內，臨床診斷領域預計將佔據體液分析市場應用領域中最大的佔有率。”

根據應用領域，體液分析市場可細分為臨床診斷、法醫學和調查應用。由於體液分析在神經系統疾病、感染疾病、癌症、發炎性疾病和生殖系統疾病的診斷和監測中應用日益廣泛，臨床診斷領域佔據了最大的市場佔有率。臨床檢查室和醫院廣泛採用流式細胞技術、免疫檢測、臨床化學和分子診斷等技術來分析腦脊髓液、胸膜液、腹水、滑液和其他特殊體液。此外，對疾病早期檢測、精準診斷和循證臨床決策的日益重視，也推動了常規醫療環境中對體液分析需求的持續成長，使得臨床診斷成為該市場中規模最大且成長最快的應用領域。

“在整個預測期內，臨床化學預計將佔據體液分析市場最大的佔有率。”

全球體液分析市場可依技術細分為顯微鏡、臨床化學、流式細胞技術、免疫檢測分析、聚合酵素鏈鎖反應(PCR) 和其他技術。其中，臨床化學領域預計將在預測期內佔據最大的市場佔有率。由於其已確立的臨床效用、在醫療機構的廣泛應用以及支持快速診斷決策的能力，臨床化學檢測仍然是常規體液評估的重要組成部分。此外，自動化化學分析儀的不斷進步、檢測量的增加以及對標準化診斷流程日益成長的需求，預計將推動全球範圍內基於臨床化學的體液分析技術的持續應用。

“亞太地區：2026年至2031年體液分析檢測市場成長最快的地區”

全球體液分析市場按地區分類為北美、歐洲、亞太、拉丁美洲以及中東和非洲。預計2026年至2031年間，亞太地區的複合年成長率將高於其他地區。在日本，人口老化推動了對腦脊髓液（CSF）診斷神經退化性疾病的需求。在中國，國家醫療現代化計畫正在擴大醫院檢查室能力。在印度，自動化體液分析系統正在三級醫院網路和私立診斷中心得到應用。

體液分析市場的主要參與者包括：Sysmex Corporation（日本）、F. Hoffmann-La Roche Ltd.（瑞士）、Danaher Corporation（美國）、bioMerieux SA（法國）、Abbott Laboratories（美國）、Thermo Fisher Scientific Inc.（美國）、QIAGEN NV（荷蘭）、Revvity, Inc. Company（美國）、HORIBA, Ltd.（日本）、Bio-Rad Laboratories, Inc.（美國）和DiaSorin SpA（義大利）。

調查範圍：

本研究報告按產品（耗材和設備）、技術（顯微鏡、臨床化學、流式細胞技術、免疫檢測分析、聚合酵素鏈鎖反應及其他技術）、類型（採集裝置和診斷產品）、體液類型（腦脊髓液、胸膜液、腹水、滑液、精液、心包膜液）、應用（臨床診斷、法醫學、調查）、最終用戶（醫院檢查室、診斷檢查室、刑事鑑定實驗室、學術和研究機構、製藥和生物技術公司）以及地區（北美、歐洲、亞太、拉丁美洲、中東和非洲）對體液分析市場進行細分。本報告涵蓋影響體液分析市場成長的關鍵因素（促進因素、阻礙因素、挑戰等）的詳細資訊。本報告對主要產業參與者進行了詳細分析，深入剖析了他們的業務概況、解決方案、收購、合作協議、關鍵策略（例如產品和服務發布）以及體液分析市場的最新趨勢。此外，報告也對體液分析市場生態系統中新興的新創公司進行了競爭分析。

購買本報告的理由：

本報告透過提供整體市場及各細分市場收入的最準確預測，幫助體液分析市場的市場領導和新參與企業。它幫助相關人員了解市場格局，更好地定位自身業務，並獲得更深入的洞察，從而製定合適的打入市場策略。此外，本報告還幫助相關人員掌握市場趨勢，並提供關鍵市場促進因素和挑戰的資訊。

本報告深入分析了以下幾點：

  • 本報告分析了影響體液分析市場成長的關鍵促進因素（全球疾病負擔加重、生殖健康障礙和不孕症患病率上升以及人們對早期疾病檢測意識的增強）、阻礙因素（缺乏標準化的報銷機制、設備和耗材高成本以及熟練的實驗室技術人員短缺）、機遇（新興經濟體的擴張潛力以及診斷技術的中斷）和挑戰挑戰（以及嚴格的監管機構）和挑戰（嚴格的監管要求）這些因素共同影響著體液分析市場的成長。
  • 產品開發/創新：對體液分析市場的未來技術趨勢、研發活動和新產品發布進行詳細分析。
  • 市場發展：盈利市場的全面資訊－本報告分析了各個地區的體液分析市場。
  • 市場多元化：全面介紹體液分析市場的新產品、未開發的市場、近期趨勢和投資狀況。
  • 競爭分析：對丹納赫（美國）、羅氏（瑞士）、賽默飛世爾科技（美國）、貝克頓·迪金森公司（美國）和雅培（美國）等主要參與者的市場佔有率、成長策略和產品陣容進行詳細評估。

目錄

第1章：引言

第2章執行摘要

第3章重要考察

第4章 市場概覽

  • 市場動態
    • 促進因素
    • 抑制因子
    • 機會
    • 任務
  • 未滿足的需求和未開發的領域
  • 相互關聯的市場與跨產業機遇
  • 一級/二級/三級公司的策略性舉措

第5章 產業趨勢

  • 波特五力分析
  • 宏觀經濟展望
  • 供應鏈分析
  • 價值鏈分析
  • 生態系分析
  • 價格分析
  • 貿易分析
  • 2026-2027 年主要會議和活動
  • 影響我們客戶公司業務的趨勢/變化
  • 投資和資金籌措場景
  • 案例研究分析
  • 美國關稅對體液分析市場的影響

第6章：技術進步、人工智慧的影響、專利、創新與未來應用

  • 主要新興技術
  • 互補技術
  • 鄰近技術
  • 技術/產品藍圖
  • 專利分析
  • 未來應用
  • 人工智慧/生成式人工智慧對體液分析市場的影響

第7章：監理情勢與永續性舉措

  • 當地法規和合規性
  • 對永續性的承諾
  • 對永續性和監管政策舉措的影響

第8章：顧客趨勢與購買行為

  • 決策流程
  • 買方相關人員和採購評估標準
  • 實施障礙和內部挑戰
  • 各個終端用戶產業尚未滿足的需求
  • 市場盈利

第9章 體液分析市場（依產品分類）

  • 消耗品
  • 裝置

第10章 體液分析市場（依技術分類）

  • 顯微鏡檢查
  • 臨床化學
  • 流式細胞技術
  • 免疫檢測
  • 聚合酵素鏈鎖反應
  • 其他

第11章：體液分析市場（按類型分類）

  • 收集裝置
  • 診斷產品

第12章：體液分析市場（以體液類型分類）

  • 腦脊髓液
  • 胸腔積水
  • 腹水
  • 滑液
  • 精液
  • 心包膜積液

第13章：體液分析市場定量分析（依體液類型、偵測次數分類）

第14章 體液分析市場（依應用領域分類）

  • 臨床診斷
  • 法醫
  • 研究

第15章：體液分析市場（依最終用戶分類）

  • 醫院檢查室
  • 診斷檢查室
  • 法醫學研究所
  • 學術和研究機構
  • 製藥和生物技術公司

第16章：體液分析市場（依地區分類）

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他
  • 拉丁美洲
    • 疾病發病率上升和醫療基礎設施改善正在推動市場發展。
  • 中東和非洲
    • 醫療保健投資的激增正在推動經濟成長。

第17章 競爭格局

  • 主要參與企業的策略/優勢
  • 2023-2025年收入分析
  • 2025年市佔率分析
  • 企業估值矩陣：主要公司，2025 年
  • 公司估值矩陣：新創企業/中小企業，2025 年
  • 企業估值和財務指標
  • 產品對比
  • 競爭格局

第18章：公司簡介

  • 主要參與企業
    • DANAHER
    • F. HOFFMANN-LA ROCHE LTD
    • BECTON, DICKINSON AND COMPANY（BD）
    • ABBOTT
    • THERMO FISHER SCIENTIFIC INC.
    • SIEMENS HEALTHINEERS AG
    • BIOMERIEUX
    • SYSMEX CORPORATION
    • BIO-RAD LABORATORIES
    • QIAGEN
    • REVVITY
    • DIASORIN SPA
    • HORIBA, LTD.
  • 其他公司
    • SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    • VIRCELL SL
    • FUJIREBIO
    • ERBA GROUP
    • GUANGZHOU WONDFO BIOTECH CO., LTD.
    • MESO SCALE DIAGNOSTICS, LLC
    • RANDOX LABORATORIES LTD.
    • AMPRION DIAGNOSTICS
    • ATILA BIOSYSTEMS
    • QUANTERIX
    • ALAMAR BIOSCIENCES
    • GENEPROOF

第19章：調查方法

第20章附錄

Product Code: MD 10551

The body fluid analysis market is projected to grow from USD 2.62 billion in 2026 to USD 3.65 billion by 2031, growing at a CAGR of 6.9%. The increasing prevalence of neurological disorders such as Alzheimer's disease and Parkinson's disease is driving demand for cerebrospinal fluid (CSF) biomarker testing, while the growing incidence of musculoskeletal disorders and periprosthetic joint infections is expanding the use of synovial fluid analysis.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsBy Product, Technology, Type, Fluid Type, Application, End User
Regions coveredNorth America, Europe, APAC, LATAM, MEA

Furthermore, advancements in automated analyzers, flow cytometry, immunoassays, and molecular diagnostic technologies are improving the accuracy, efficiency, and standardization of specialty body fluid testing. These innovations are enabling healthcare providers to make more informed diagnostic and treatment decisions, thereby supporting market growth.

Body Fluid Analysis Market - IMG1

"The clinical diagnostics segment is expected to account for the largest share of the body fluid analysis market, by application, during the forecast period."

Depending on the application, the body fluid analysis market is classified into clinical diagnostics, forensics, and research applications. The clinical diagnostics segment accounts for the largest market share due to the increasing use of body fluid analysis for the diagnosis and monitoring of neurological disorders, infections, cancers, inflammatory conditions, and reproductive health disorders. Clinical laboratories and hospitals extensively utilize technologies such as flow cytometry, immunoassays, clinical chemistry, and molecular diagnostics to analyze cerebrospinal fluid (CSF), pleural fluid, peritoneal fluid, synovial fluid, and other specialty body fluids. Additionally, the growing emphasis on early disease detection, precision diagnostics, and evidence-based clinical decision-making continues to drive demand for body fluid analysis in routine healthcare settings, making clinical diagnostics the largest and fastest-growing application segment of the market.

"The clinical chemistry is likely to capture the largest share of the body fluid analysis market throughout the forecast period."

The global body fluid analysis market can be segmented by technology into microscopic examination, clinical chemistry, flow cytometry, immunoassay, polymerase chain reaction (PCR), and other technologies. Among these, the clinical chemistry segment is likely to account for the largest market share throughout the forecast period. Clinical chemistry testing remains a fundamental component of routine body fluid evaluation due to its established clinical utility, broad availability across healthcare facilities, and ability to support rapid diagnostic decision-making. Furthermore, continuous advancements in automated chemistry analyzers, increasing laboratory testing volumes, and growing demand for standardized diagnostic workflows are expected to support the continued adoption of clinical chemistry-based body fluid analysis worldwide.

"Asia Pacific: The fastest-growing market for body fluid analysis testing from 2026 to 2031"

The global body fluid analysis market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa. Asia Pacific is projected to grow at the highest regional CAGR from 2026 to 2031. Japan has a large aging population driving demand for CSF-based neurodegenerative diagnostics. China is expanding hospital laboratory capacity through national health modernization programs. India's network of tertiary-care hospitals and private diagnostic centers is adopting automated body fluid analysis systems.

The break-up of the profile of primary participants in the body fluid analysis market:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier - 30%
  • By Designation: C-level Executives - 27%, Directors - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa - 4%

Sysmex Corporation (Japan); F. Hoffmann-La Roche Ltd. (Switzerland); Danaher Corporation (US); bioMerieux SA (France); Abbott Laboratories (US); Thermo Fisher Scientific Inc. (US); QIAGEN N.V. (Netherlands); Revvity, Inc. (US); Siemens Healthineers AG (Germany); Becton, Dickinson and Company (US); HORIBA, Ltd. (Japan); Bio-Rad Laboratories, Inc. (US); and DiaSorin S.p.A. (Italy) are some of the key players in the body fluid analysis market.

Research Coverage:

This research report categorizes the body fluid analysis market by product (consumables and instruments), by technology (microscopic examination, clinical chemistry, flow cytometry, immunoassay, polymerase chain reaction, and other technologies), by type (collection devices and diagnostic products), by fluid type (cerebrospinal fluid, pleural fluid, peritoneal fluid, synovial fluid, semen, and pericardial fluid), by application (clinical diagnostics, forensic, and research), by end user (hospital laboratories, diagnostic laboratories, forensic laboratories, academic and research institutes, and pharmaceutical and biotechnology companies), and by region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the body fluid analysis market. A detailed analysis of the key industry players has been done to provide insights into their business overview; solutions; key strategies such as acquisitions, agreements, and product & service launches; and recent developments associated with the body fluid analysis market. Competitive analysis of upcoming startups in the body fluid analysis market ecosystem is covered in this report.

Reasons to Buy This Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall body fluid analysis market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (growing global disease burden, increasing prevalence of reproductive health conditions and infertility, growing awareness of early disease detection), restraints (lack of standardized reimbursement structures, high cost of instruments and consumables, shortage of skilled laboratory personnel), opportunities (expansion potential across emerging economies, advancements in diagnostic technologies), and challenges (stringent and varying regulatory requirements, supply chain disruptions for reagents and kits) influencing the growth of the body fluid analysis market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the body fluid analysis market.
  • Market Development: Comprehensive information about lucrative markets-the report analyzes the body fluid analysis market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the body fluid analysis market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Danaher (US); F. Hoffmann-La Roche Ltd. (Switzerland); Thermo Fisher Scientific Inc. (US); Becton, Dickinson and Company (US); and Abbott (US).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
  • 2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
  • 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 BODY FLUID ANALYSIS MARKET OVERVIEW
  • 3.2 BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2026 VS. 2031
  • 3.3 BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2026 VS. 2031
  • 3.4 BODY FLUID ANALYSIS MARKET, BY TYPE, 2026 VS. 2031
  • 3.5 BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2026 VS. 2031
  • 3.6 BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2026 VS. 2031
  • 3.7 BODY FLUID ANALYSIS MARKET, BY END USER, 2026 VS. 2031
  • 3.8 BODY FLUID ANALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Growing global infectious disease, inflammatory disease, and cancer burden necessitating body fluid analysis
      • 4.2.1.2 Increasing prevalence of reproductive health conditions and infertility
      • 4.2.1.3 Growing awareness of early disease detection
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Limited and inconsistent reimbursement for advanced body fluid testing
      • 4.2.2.2 High cost of instruments and consumables
      • 4.2.2.3 Shortage of skilled laboratory personnel
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Expansion potential across emerging economies
      • 4.2.3.2 Advancements in diagnostic technologies
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Stringent and varying regulatory requirements
      • 4.2.4.2 Supply chain disruptions for reagents and kits
  • 4.3 UNMET NEEDS AND WHITE SPACES
    • 4.3.1 UNMET NEEDS IN BODY FLUID ANALYSIS MARKET
    • 4.3.2 WHITE SPACE OPPORTUNITIES
  • 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
    • 4.4.1 INTERCONNECTED MARKETS
    • 4.4.2 CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
    • 4.5.1 KEY MOVES AND STRATEGIC FOCUS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 BARGAINING POWER OF SUPPLIERS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 THREAT OF NEW ENTRANTS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS AND FORECAST
  • 5.3 SUPPLY CHAIN ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
    • 5.5.1 BODY FLUID ANALYSIS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • 5.6 PRICING ANALYSIS
    • 5.6.1 AVERAGE SELLING PRICE OF BODY FLUID ANALYSIS PRODUCTS, BY KEY PLAYER, 2024-2026
    • 5.6.2 AVERAGE SELLING PRICE OF BODY FLUID ANALYSIS PRODUCTS, BY REGION, 2024-2026
  • 5.7 TRADE ANALYSIS
    • 5.7.1 IMPORT SCENARIO (HS CODE 3822)
    • 5.7.2 EXPORT SCENARIO (HS CODE 3822)
  • 5.8 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.10 INVESTMENT & FUNDING SCENARIO
  • 5.11 CASE STUDY ANALYSIS
    • 5.11.1 CASE STUDY 1: IMPLEMENTATION OF AUTOMATED CSF ALZHEIMER'S BIOMARKER TESTING USING ROCHE ELECSYS ASSAYS
    • 5.11.2 CASE STUDY 2: IMPLEMENTATION OF AUTOMATED BODY FLUID CELL COUNTING USING BECKMAN COLTER UNICEL DXH SERIES
    • 5.11.3 CASE STUDY 3: POINT-OF-CARE TESTING FOR PLEURAL, PERITONEAL, AND CSF ANALYSIS
  • 5.12 IMPACT OF US TARIFFS-BODY FLUID ANALYSIS MARKET
    • 5.12.1 INTRODUCTION
    • 5.12.2 KEY TARIFF RATES
    • 5.12.3 PRICE IMPACT ANALYSIS
    • 5.12.4 IMPACT ON COUNTRIES/REGIONS
      • 5.12.4.1 North America
      • 5.12.4.2 Europe
      • 5.12.4.3 Asia Pacific
    • 5.12.5 IMPACT ON END-USE INDUSTRIES
      • 5.12.5.1 Diagnostic laboratories
      • 5.12.5.2 Hospital laboratories
      • 5.12.5.3 Forensic laboratories
      • 5.12.5.4 Academic & research institutes
      • 5.12.5.5 Pharmaceutical & biotechnology companies

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 FLOW CYTOMETRY
    • 6.1.2 PCR
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 BIOINFORMATICS & DATA ANALYTICS PLATFORMS
  • 6.3 ADJACENT TECHNOLOGIES
    • 6.3.1 DIGITAL PCR (DPCR)
  • 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.5 PATENT ANALYSIS
    • 6.5.1 LIST OF MAJOR PATENTS
  • 6.6 FUTURE APPLICATIONS
  • 6.7 IMPACT OF AI/GENERATIVE AI ON BODY FLUID ANALYSIS MARKET
    • 6.7.1 INTRODUCTION
    • 6.7.2 TOP USE CASES AND MARKET POTENTIAL
    • 6.7.3 KEY COMPANIES IMPLEMENTING AI
    • 6.7.4 FUTURE OF AI

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    • 7.1.1 REGULATORY ANALYSIS
      • 7.1.1.1 North America
        • 7.1.1.1.1 US
        • 7.1.1.1.2 Canada
      • 7.1.1.2 Europe
        • 7.1.1.2.1 Germany
        • 7.1.1.2.2 UK
        • 7.1.1.2.3 France
        • 7.1.1.2.4 Italy
      • 7.1.1.3 Asia Pacific
        • 7.1.1.3.1 China
        • 7.1.1.3.2 Japan
        • 7.1.1.3.3 India
      • 7.1.1.4 Latin America
        • 7.1.1.4.1 Brazil
        • 7.1.1.4.2 Mexico
      • 7.1.1.5 Middle East
        • 7.1.1.5.1 Africa
    • 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.2 SUSTAINABILITY INITIATIVES
    • 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN BODY FLUID ANALYSIS MARKET
      • 7.2.1.1 Eco-friendly Initiatives
  • 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • 8.5 MARKET PROFITABILITY
    • 8.5.1 REVENUE POTENTIAL
    • 8.5.2 COST DYNAMICS
    • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 BODY FLUID ANALYSIS MARKET, BY PRODUCT

  • 9.1 INTRODUCTION
  • 9.2 CONSUMABLES
    • 9.2.1 ONGOING INNOVATIONS IN BODY FLUID ANALYSIS TO SPUR GROWTH
  • 9.3 INSTRUMENTS
    • 9.3.1 TECHNOLOGICAL ADVANCEMENTS TO FOSTER MARKET GROWTH

10 BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY

  • 10.1 INTRODUCTION
  • 10.2 MICROSCOPIC EXAMINATION
    • 10.2.1 GROWING ADOPTION OF AUTOMATED AND DIGITAL MICROSCOPY TO DRIVE MARKET
  • 10.3 CLINICAL CHEMISTRY
    • 10.3.1 RISING DEMAND FOR RAPID AND ACCURATE BIOCHEMICAL ASSESSMENT FUELS ADOPTION OF CLINICAL CHEMISTRY TECHNOLOGY
  • 10.4 FLOW CYTOMETRY
    • 10.4.1 ADVANCEMENTS IN MULTIPARAMETRIC ANALYSIS AND AUTOMATION DRIVE THE MARKET GROWTH
  • 10.5 IMMUNOASSAY
    • 10.5.1 INCREASING USE OF IMMUNOASSAYS IN CANCER AND INFECTIOUS DISEASE TESTING TO AID GROWTH
  • 10.6 POLYMERASE CHAIN REACTION
    • 10.6.1 NEED FOR HIGH PRECISION FOR DISEASE IDENTIFICATION TO SUPPORT GROWTH
  • 10.7 OTHER TECHNOLOGIES

11 BODY FLUID ANALYSIS MARKET, BY TYPE

  • 11.1 INTRODUCTION
  • 11.2 COLLECTION DEVICES
    • 11.2.1 RISING DEMAND FOR ACCURATE SPECIMEN COLLECTION AND HANDLING TO PROMOTE GROWTH
  • 11.3 DIAGNOSTIC PRODUCTS
    • 11.3.1 TECHNOLOGICAL ADVANCEMENTS TO AUGMENT GROWTH

12 BODY FLUID ANALYSIS MARKET, BY FLUID TYPE

  • 12.1 INTRODUCTION
  • 12.2 CEREBROSPINAL FLUID
    • 12.2.1 INCREASING BURDEN OF NEUROLOGICAL DISORDERS SUPPORTS MARKET GROWTH
  • 12.3 PLEURAL FLUID
    • 12.3.1 TECHNOLOGICAL ADVANCEMENTS IMPROVING DIAGNOSTIC ACCURACY OF PLEURAL FLUID TESTING TO DRIVE MARKET
  • 12.4 PERITONEAL FLUID
    • 12.4.1 RISING PREVALENCE OF LIVER DISORDERS AND MALIGNANT ASCITES DRIVES MARKET
  • 12.5 SYNOVIAL FLUID
    • 12.5.1 GROWING AWARENESS ABOUT DISEASE SURVEILLANCE, SCREENING, AND OUTBREAK RESPONSE TO DRIVE MARKET
  • 12.6 SEMEN
    • 12.6.1 DECLINING MALE REPRODUCTIVE HEALTH DRIVING DEMAND FOR SEMEN ANALYSIS
  • 12.7 PERICARDIAL FLUID
    • 12.7.1 GROWING UTILIZATION OF PERICARDIAL FLUID TESTING IN CLINICAL PRACTICES TO DRIVE MARKET

13 BODY FLUID ANALYSIS MARKET VOLUME ANALYSIS, BY FLUID TYPE (NUMBER OF TESTS)

14 BODY FLUID ANALYSIS MARKET, BY APPLICATION

  • 14.1 INTRODUCTION
  • 14.2 CLINICAL DIAGNOSTICS
    • 14.2.1 INFECTIOUS DISEASES
      • 14.2.1.1 Rising burden of infectious diseases drives adoption of body fluid analysis
    • 14.2.2 INFLAMMATORY DISEASES
      • 14.2.2.1 Growing burden of autoimmune and inflammatory diseases supports market growth
    • 14.2.3 CANCER
      • 14.2.3.1 Rising burden of cancer to fuel growth
    • 14.2.4 OTHER DISEASES
  • 14.3 FORENSICS
    • 14.3.1 GROWING UTILIZATION OF BODY FLUID ANALYSIS IN FORENSIC AND MEDICO-LEGAL INVESTIGATIONS TO SUPPORT MARKET
  • 14.4 RESEARCH
    • 14.4.1 INCREASING USE OF BODY FLUID ANALYSIS IN BIOMEDICAL RESEARCH AND BIOMARKER DISCOVERY TO BOOST MARKET

15 BODY FLUID ANALYSIS MARKET, BY END USER

  • 15.1 INTRODUCTION
  • 15.2 HOSPITAL LABORATORIES
    • 15.2.1 RISING HEALTHCARE INVESTMENT TO CONTRIBUTE TO GROWTH
  • 15.3 DIAGNOSTIC LABORATORIES
    • 15.3.1 GROWING EMPHASIS ON QUALITY CONTROL AND STANDARDIZED TESTING PROTOCOLS TO BOOST MARKET
  • 15.4 FORENSIC LABORATORIES
    • 15.4.1 ADVANCEMENTS IN FORENSIC TESTING AND LABORATORY INFORMATICS SUPPORT MARKET GROWTH
  • 15.5 ACADEMIC & RESEARCH INSTITUTES
    • 15.5.1 ADVANCEMENTS IN RESEARCH TO BOOST MARKET
  • 15.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 15.6.1 INCREASING ADOPTION OF BIOMARKER-DRIVEN DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH

16 BODY FLUID ANALYSIS MARKET, BY REGION

  • 16.1 INTRODUCTION
  • 16.2 NORTH AMERICA
    • 16.2.1 US
      • 16.2.1.1 Presence of advanced healthcare infrastructure to augment growth
    • 16.2.2 CANADA
      • 16.2.2.1 Favorable government initiatives to fuel market
  • 16.3 EUROPE
    • 16.3.1 GERMANY
      • 16.3.1.1 Increasing healthcare expenditure to advance growth
    • 16.3.2 UK
      • 16.3.2.1 Growing number of diagnostic centers to fuel market
    • 16.3.3 FRANCE
      • 16.3.3.1 Increasing demand for early disease diagnosis to augment growth
    • 16.3.4 ITALY
      • 16.3.4.1 Growing adoption of advanced diagnostic technologies to fuel market
    • 16.3.5 SPAIN
      • 16.3.5.1 Increased government initiatives to boost market
    • 16.3.6 REST OF EUROPE
  • 16.4 ASIA PACIFIC
    • 16.4.1 CHINA
      • 16.4.1.1 Rising public access to modern healthcare to spur growth
    • 16.4.2 JAPAN
      • 16.4.2.1 Universal healthcare reimbursement policy to foster growth
    • 16.4.3 INDIA
      • 16.4.3.1 Increased government investments for healthcare sector to bolster growth
    • 16.4.4 REST OF ASIA PACIFIC
  • 16.5 LATIN AMERICA
    • 16.5.1 RISING DISEASE INCIDENCE AND HEALTHCARE INFRASTRUCTURAL IMPROVEMENTS TO DRIVE MARKET
  • 16.6 MIDDLE EAST & AFRICA
    • 16.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH

17 COMPETITIVE LANDSCAPE

  • 17.1 INTRODUCTION
  • 17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 17.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN BODY FLUID ANALYSIS MARKET
  • 17.3 REVENUE ANALYSIS, 2023-2025
  • 17.4 MARKET SHARE ANALYSIS, 2025
    • 17.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
    • 17.4.2 US MARKET SHARE ANALYSIS, 2025
  • 17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 17.5.1 STARS
    • 17.5.2 EMERGING LEADERS
    • 17.5.3 PERVASIVE PLAYERS
    • 17.5.4 PARTICIPANTS
    • 17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 17.5.5.1 Company footprint
      • 17.5.5.2 Region footprint
      • 17.5.5.3 Product footprint
      • 17.5.5.4 Type footprint
      • 17.5.5.5 Application footprint
  • 17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 17.6.1 PROGRESSIVE COMPANIES
    • 17.6.2 RESPONSIVE COMPANIES
    • 17.6.3 DYNAMIC COMPANIES
    • 17.6.4 STARTING BLOCKS
    • 17.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
      • 17.6.5.1 Detailed list of key startups/SMEs
      • 17.6.5.2 Competitive benchmarking of startups/SMEs
  • 17.7 COMPANY VALUATION & FINANCIAL METRICS
    • 17.7.1 FINANCIAL METRICS
    • 17.7.2 COMPANY VALUATION
  • 17.8 PRODUCT COMPARISON
  • 17.9 COMPETITIVE SCENARIO
    • 17.9.1 PRODUCT LAUNCHES & APPROVALS
    • 17.9.2 DEALS
    • 17.9.3 EXPANSIONS

18 COMPANY PROFILES

  • 18.1 KEY PLAYERS
    • 18.1.1 DANAHER
      • 18.1.1.1 Business overview
      • 18.1.1.2 Products offered
      • 18.1.1.3 Recent developments
        • 18.1.1.3.1 Deals
      • 18.1.1.4 MnM view
        • 18.1.1.4.1 Key strengths
        • 18.1.1.4.2 Strategic choices
        • 18.1.1.4.3 Weaknesses and competitive threats
    • 18.1.2 F. HOFFMANN-LA ROCHE LTD
      • 18.1.2.1 Business overview
      • 18.1.2.2 Products offered
      • 18.1.2.3 Recent developments
        • 18.1.2.3.1 Product launches & approvals
      • 18.1.2.4 MnM view
        • 18.1.2.4.1 Key strengths
        • 18.1.2.4.2 Strategic choices
        • 18.1.2.4.3 Weaknesses and competitive threats
    • 18.1.3 BECTON, DICKINSON AND COMPANY (BD)
      • 18.1.3.1 Business overview
      • 18.1.3.2 Products offered
      • 18.1.3.3 MnM view
        • 18.1.3.3.1 Key strengths
        • 18.1.3.3.2 Strategic choices
        • 18.1.3.3.3 Weaknesses and competitive threats
    • 18.1.4 ABBOTT
      • 18.1.4.1 Business overview
      • 18.1.4.2 Products offered
      • 18.1.4.3 MnM view
        • 18.1.4.3.1 Key strengths
        • 18.1.4.3.2 Strategic choices
        • 18.1.4.3.3 Weaknesses & competitive threats
    • 18.1.5 THERMO FISHER SCIENTIFIC INC.
      • 18.1.5.1 Business overview
      • 18.1.5.2 Products offered
      • 18.1.5.3 Recent developments
        • 18.1.5.3.1 Expansions
      • 18.1.5.4 MnM view
        • 18.1.5.4.1 Key strengths
        • 18.1.5.4.2 Strategic choices
        • 18.1.5.4.3 Weaknesses and competitive threats
    • 18.1.6 SIEMENS HEALTHINEERS AG
      • 18.1.6.1 Business overview
      • 18.1.6.2 Products offered
      • 18.1.6.3 Recent developments
        • 18.1.6.3.1 Deals
        • 18.1.6.3.2 Expansions
    • 18.1.7 BIOMERIEUX
      • 18.1.7.1 Business overview
      • 18.1.7.2 Products offered
    • 18.1.8 SYSMEX CORPORATION
      • 18.1.8.1 Business overview
      • 18.1.8.2 Products offered
      • 18.1.8.3 Recent developments
        • 18.1.8.3.1 Deals
    • 18.1.9 BIO-RAD LABORATORIES
      • 18.1.9.1 Business overview
      • 18.1.9.2 Products offered
    • 18.1.10 QIAGEN
      • 18.1.10.1 Business overview
      • 18.1.10.2 Products offered
      • 18.1.10.3 Recent developments
        • 18.1.10.3.1 Product launches and approvals
    • 18.1.11 REVVITY
      • 18.1.11.1 Business overview
      • 18.1.11.2 Products offered
    • 18.1.12 DIASORIN S.P.A.
      • 18.1.12.1 Business overview
      • 18.1.12.2 Products offered
    • 18.1.13 HORIBA, LTD.
      • 18.1.13.1 Business overview
      • 18.1.13.2 Products offered
  • 18.2 OTHER PLAYERS
    • 18.2.1 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    • 18.2.2 VIRCELL S.L.
    • 18.2.3 FUJIREBIO
    • 18.2.4 ERBA GROUP
    • 18.2.5 GUANGZHOU WONDFO BIOTECH CO., LTD.
    • 18.2.6 MESO SCALE DIAGNOSTICS, LLC
    • 18.2.7 RANDOX LABORATORIES LTD.
    • 18.2.8 AMPRION DIAGNOSTICS
    • 18.2.9 ATILA BIOSYSTEMS
    • 18.2.10 QUANTERIX
    • 18.2.11 ALAMAR BIOSCIENCES
    • 18.2.12 GENEPROOF

19 RESEARCH METHODOLOGY

  • 19.1 RESEARCH DATA
    • 19.1.1 SECONDARY DATA
      • 19.1.1.1 List of secondary sources
      • 19.1.1.2 Key data from secondary sources
    • 19.1.2 PRIMARY DATA
      • 19.1.2.1 List of primary sources
      • 19.1.2.2 Key data from primary sources
      • 19.1.2.3 Key industry insights
      • 19.1.2.4 Breakdown of primary interviews
  • 19.2 MARKET SIZE ESTIMATION
    • 19.2.1 TOTAL MARKET SIZE: BODY FLUID ANALYSIS MARKET
    • 19.2.2 BOTTOM-UP APPROACH
      • 19.2.2.1 Approach 1: Revenue estimation of key players
      • 19.2.2.2 Approach 2: Study of annual reports and investor presentations
      • 19.2.2.3 Approach 3: Primary interviews
      • 19.2.2.4 Growth forecast
      • 19.2.2.5 CAGR projections
    • 19.2.3 TOP-DOWN APPROACH
  • 19.3 DATA TRIANGULATION
  • 19.4 RESEARCH ASSUMPTIONS
    • 19.4.1 STUDY-RELATED ASSUMPTIONS
  • 19.5 STUDY ASSUMPTIONS
    • 19.5.1 PARAMETRIC ASSUMPTIONS
    • 19.5.2 GROWTH RATE ASSUMPTIONS
  • 19.6 RESEARCH LIMITATIONS
  • 19.7 RISK ASSESSMENT

20 APPENDIX

  • 20.1 DISCUSSION GUIDE
  • 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 20.3 CUSTOMIZATION OPTIONS
  • 20.4 RELATED REPORTS
  • 20.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 BODY FLUID ANALYSIS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023-2030
  • TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 4 NORTH AMERICA: COUNTRY-WISE MACROECONOMIC INDICATORS
  • TABLE 5 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 6 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 7 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 8 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 9 AVERAGE SELLING PRICE OF BODY FLUID ANALYSIS PRODUCTS, BY KEY PLAYER, 2024-2026 (USD)
  • TABLE 10 AVERAGE SELLING PRICE OF BODY FLUID ANALYSIS PRODUCTS, BY REGION, 2024-2026 (USD)
  • TABLE 11 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 12 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 13 BODY FLUID ANALYSIS MARKET: KEY CONFERENCES AND EVENTS, 2026-2027
  • TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 15 KEY PATENTS IN BODY FLUID ANALYSIS MARKET, 2022-2026
  • TABLE 16 KEY COMPANIES IMPLEMENTING AI IN BODY FLUID ANALYSIS MARKET
  • TABLE 17 CLASSIFICATION OF IVD DEVICES IN EUROPE
  • TABLE 18 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
  • TABLE 19 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 22 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 23 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%)
  • TABLE 25 KEY BUYING CRITERIA, BY PRODUCT
  • TABLE 26 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • TABLE 27 BODY FLUID ANALYSIS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • TABLE 28 BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 29 CONSUMABLES OFFERED BY KEY PLAYERS
  • TABLE 30 BODY FLUID ANALYSIS CONSUMABLES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 31 NORTH AMERICA: BODY FLUID ANALYSIS CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 32 EUROPE: BODY FLUID ANALYSIS CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 33 ASIA PACIFIC: BODY FLUID ANALYSIS CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 34 TESTING INSTRUMENTS OFFERED BY KEY PLAYERS
  • TABLE 35 BODY FLUID ANALYSIS INSTRUMENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 36 NORTH AMERICA: BODY FLUID ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 37 EUROPE: BODY FLUID ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 38 ASIA PACIFIC: BODY FLUID ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 39 BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 40 MICROSCOPIC EXAMINATION-BASED TESTS AND DEVICES OFFERED BY KEY PLAYERS
  • TABLE 41 BODY FLUID ANALYSIS MARKET FOR MICROSCOPIC EXAMINATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 42 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR MICROSCOPIC EXAMINATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 43 EUROPE: BODY FLUID ANALYSIS MARKET FOR MICROSCOPIC EXAMINATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 44 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR MICROSCOPIC EXAMINATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 45 CLINICAL CHEMISTRY TECHNOLOGY-BASED TESTS AND DEVICES OFFERED BY KEY PLAYERS
  • TABLE 46 BODY FLUID ANALYSIS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 47 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 48 EUROPE: BODY FLUID ANALYSIS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 50 BODY FLUID ANALYSIS MARKET FOR FLOW CYTOMETRY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 51 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 52 EUROPE: BODY FLUID ANALYSIS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 53 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 54 IMMUNOASSAY PRODUCTS OFFERED BY KEY PLAYERS
  • TABLE 55 BODY FLUID ANALYSIS MARKET FOR IMMUNOASSAY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 56 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR IMMUNOASSAY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 57 EUROPE: BODY FLUID ANALYSIS MARKET FOR IMMUNOASSAY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 58 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR IMMUNOASSAY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 59 PCR-BASED TESTS AND DEVICES OFFERED BY KEY PLAYERS
  • TABLE 60 BODY FLUID ANALYSIS MARKET FOR PCR, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 61 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 62 EUROPE: BODY FLUID ANALYSIS MARKET FOR PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 63 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 64 BODY FLUID ANALYSIS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 65 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 66 EUROPE: BODY FLUID ANALYSIS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 68 BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 69 BODY FLUID ANALYSIS MARKET FOR COLLECTION DEVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 70 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR COLLECTION DEVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 71 EUROPE: BODY FLUID ANALYSIS MARKET FOR COLLECTION DEVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR COLLECTION DEVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 73 DIAGNOSTIC PRODUCTS OFFERED BY KEY PLAYERS
  • TABLE 74 BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC PRODUCTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 75 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 76 EUROPE: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 77 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC PRODUCTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 78 BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 79 BODY FLUID ANALYSIS MARKET FOR CSF, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 80 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR CSF, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 81 EUROPE: BODY FLUID ANALYSIS MARKET FOR CSF, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 82 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CSF, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 83 BODY FLUID ANALYSIS MARKET FOR PLEURAL FLUID, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 84 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR PLEURAL FLUID, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 85 EUROPE: BODY FLUID ANALYSIS MARKET FOR PLEURAL FLUID, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR PLEURAL FLUID, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 87 BODY FLUID ANALYSIS MARKET FOR PERITONEAL FLUID, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 88 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR PERITONEAL FLUID, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 89 EUROPE: BODY FLUID ANALYSIS MARKET FOR PERITONEAL FLUID, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 90 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR PERITONEAL FLUID, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 91 BODY FLUID ANALYSIS MARKET FOR SYNOVIAL FLUID, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 92 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR SYNOVIAL FLUID, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 93 EUROPE: BODY FLUID ANALYSIS MARKET FOR SYNOVIAL FLUID, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR SYNOVIAL FLUID, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 95 BODY FLUID ANALYSIS MARKET FOR SEMEN, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 96 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR SEMEN, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 97 EUROPE: BODY FLUID ANALYSIS MARKET FOR SEMEN, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR SEMEN, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 99 BODY FLUID ANALYSIS MARKET FOR PERICARDIAL FLUID, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 100 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR PERICARDIAL FLUID, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 101 EUROPE: BODY FLUID ANALYSIS MARKET FOR PERICARDIAL FLUID, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR PERICARDIAL FLUID, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 103 BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (IN THOUSANDS)
  • TABLE 104 BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 105 BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 106 BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 107 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 108 EUROPE: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 110 INFECTIOUS DISEASE PRODUCTS OFFERED BY KEY PLAYERS
  • TABLE 111 BODY FLUID ANALYSIS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 112 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 113 EUROPE: BODY FLUID ANALYSIS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 114 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 115 TUBERCULOSIS TESTING PRODUCTS OFFERED BY KEY PLAYERS
  • TABLE 116 BODY FLUID ANALYSIS MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 117 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 118 EUROPE: BODY FLUID ANALYSIS MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 120 INCREASING INCIDENCE OF CANCER, BY REGION, 2022 VS 2040
  • TABLE 121 BODY FLUID ANALYSIS MARKET FOR CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 122 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 123 EUROPE: BODY FLUID ANALYSIS MARKET FOR CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 125 BODY FLUID ANALYSIS MARKET FOR OTHER DISEASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 126 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 127 EUROPE: BODY FLUID ANALYSIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 128 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 129 BODY FLUID ANALYSIS MARKET FOR FORENSICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 130 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR FORENSICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 131 EUROPE: BODY FLUID ANALYSIS MARKET FOR FORENSICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 132 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR FORENSICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 133 BODY FLUID ANALYSIS MARKET FOR RESEARCH, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 134 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 135 EUROPE: BODY FLUID ANALYSIS MARKET FOR RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 136 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 137 BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 138 BODY FLUID ANALYSIS MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 139 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 140 EUROPE: BODY FLUID ANALYSIS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 141 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 142 BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 143 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 144 EUROPE: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 145 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 146 BODY FLUID ANALYSIS MARKET FOR FORENSIC LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 147 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR FORENSIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 148 EUROPE: BODY FLUID ANALYSIS MARKET FOR FORENSIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 149 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR FORENSIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 150 BODY FLUID ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 151 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 152 EUROPE: BODY FLUID ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 154 BODY FLUID ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 155 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 156 EUROPE: BODY FLUID ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 157 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 158 BODY FLUID ANALYSIS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 159 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 160 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 161 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 162 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 163 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 164 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 165 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 166 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 167 US: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 168 US: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 169 US: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 170 US: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 171 US: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 172 US: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 173 US: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 174 CANADA: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 175 CANADA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 176 CANADA: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 177 CANADA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 178 CANADA: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 179 CANADA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 180 CANADA: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 181 EUROPE: BODY FLUID ANALYSIS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 182 EUROPE: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 183 EUROPE: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 184 EUROPE: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 185 EUROPE: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 186 EUROPE: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 187 EUROPE: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 188 EUROPE: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 189 GERMANY: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 190 GERMANY: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 191 GERMANY: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 192 GERMANY: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 193 GERMANY: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 194 GERMANY: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 195 GERMANY: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 196 UK: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 197 UK: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 198 UK: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 199 UK: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 200 UK: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 201 UK: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 202 UK: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 203 FRANCE: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 204 FRANCE: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 205 FRANCE: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 206 FRANCE: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 207 FRANCE: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 208 FRANCE: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 209 FRANCE: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 210 ITALY: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 211 ITALY: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 212 ITALY: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 213 ITALY: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 214 ITALY: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 215 ITALY: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 216 ITALY: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 217 SPAIN: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 218 SPAIN: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 219 SPAIN: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 220 SPAIN: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 221 SPAIN: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 222 SPAIN: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 223 SPAIN: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 224 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 225 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 226 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 227 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 228 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 229 REST OF EUROPE: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 230 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 231 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 232 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 233 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 234 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 235 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 236 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 237 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 238 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 239 CHINA: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 240 CHINA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 241 CHINA: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 242 CHINA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 243 CHINA: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 244 CHINA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 245 CHINA: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 246 JAPAN: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 247 JAPAN: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 248 JAPAN: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 249 JAPAN: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 250 JAPAN: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 251 JAPAN: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 252 JAPAN: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 253 INDIA: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 254 INDIA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 255 INDIA: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 256 INDIA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 257 INDIA: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 258 INDIA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 259 INDIA: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 260 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 261 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 262 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 263 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 264 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 265 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 266 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 267 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 268 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 269 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 270 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 271 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 272 LATIN AMERICA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 273 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 274 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 275 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 276 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 277 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024-2031 (USD MILLION)
  • TABLE 278 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 279 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 280 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 281 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN BODY FLUID ANALYSIS MARKET, JANUARY 2023-JUNE 2026
  • TABLE 282 BODY FLUID ANALYSIS MARKET: DEGREE OF COMPETITION
  • TABLE 283 BODY FLUID ANALYSIS MARKET: REGION FOOTPRINT
  • TABLE 284 BODY FLUID ANALYSIS MARKET: PRODUCT FOOTPRINT
  • TABLE 285 BODY FLUID ANALYSIS MARKET: TYPE FOOTPRINT
  • TABLE 286 BODY FLUID ANALYSIS MARKET: APPLICATION FOOTPRINT
  • TABLE 287 BODY FLUID ANALYSIS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 288 BODY FLUID ANALYSIS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
  • TABLE 289 BODY FLUID ANALYSIS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
  • TABLE 290 BODY FLUID ANALYSIS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-JUNE 2026
  • TABLE 291 BODY FLUID ANALYSIS MARKET: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 292 BODY FLUID ANALYSIS: EXPANSIONS, JANUARY 2023-JUNE 2026
  • TABLE 293 DANAHER: COMPANY OVERVIEW
  • TABLE 294 DANAHER: PRODUCTS OFFERED
  • TABLE 295 DANAHER: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 296 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 297 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
  • TABLE 298 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 299 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW
  • TABLE 300 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED
  • TABLE 301 ABBOTT: COMPANY OVERVIEW
  • TABLE 302 ABBOTT: PRODUCTS OFFERED
  • TABLE 303 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 304 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 305 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023-APRIL 2026
  • TABLE 306 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 307 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 308 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 309 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2023-APRIL 2026
  • TABLE 310 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 311 BIOMERIEUX: PRODUCTS OFFERED
  • TABLE 312 SYSMEX: COMPANY OVERVIEW
  • TABLE 313 SYSMEX CORPORATION: PRODUCTS OFFERED
  • TABLE 314 SYSMEX CORPORATION: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 315 BIO-RAD LABORATORIES: COMPANY OVERVIEW
  • TABLE 316 BIO-RAD LABORATORIES: PRODUCTS OFFERED
  • TABLE 317 QIAGEN: COMPANY OVERVIEW
  • TABLE 318 QIAGEN: PRODUCTS OFFERED
  • TABLE 319 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 320 REVVITY: COMPANY OVERVIEW
  • TABLE 321 REVVITY: PRODUCTS OFFERED
  • TABLE 322 DIASORIN S.P.A.: COMPANY OVERVIEW
  • TABLE 323 DIASORIN S.P.A.: PRODUCTS OFFERED
  • TABLE 324 HORIBA, LTD.: COMPANY OVERVIEW
  • TABLE 325 HORIBA LTD.: PRODUCTS OFFERED
  • TABLE 326 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
  • TABLE 327 VIRCELL S.L.: COMPANY OVERVIEW
  • TABLE 328 FUJIREBIO: COMPANY OVERVIEW
  • TABLE 329 ERBA GROUP: COMPANY OVERVIEW
  • TABLE 330 GUANGZHOU WONDFO BIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 331 MESO SCALE DIAGNOSTICS LLC: COMPANY OVERVIEW
  • TABLE 332 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW
  • TABLE 333 AMPRION DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 334 ATILA BIOSYSTEMS: COMPANY OVERVIEW
  • TABLE 335 QUANTERIX: COMPANY OVERVIEW
  • TABLE 336 ALAMAR BIOSCIENCES: COMPANY OVERVIEW
  • TABLE 337 GENEPROOF: COMPANY OVERVIEW
  • TABLE 338 BODY FLUID ANALYSIS MARKET: RISK ASSESSMENT

List of Figures

  • FIGURE 1 BODY FLUID ANALYSIS MARKET SEGMENTATION
  • FIGURE 2 KEY INSIGHTS AND MARKET HIGHLIGHTS
  • FIGURE 3 GLOBAL BODY FLUID ANALYSIS MARKET, 2024-2031
  • FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BODY FLUID ANALYSIS MARKET, 2023-2025
  • FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF BODY FLUID ANALYSIS
  • FIGURE 6 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN BODY FLUID ANALYSIS MARKET, 2025
  • FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 8 RISING CASES OF CHRONIC DISEASES TO DRIVE MARKET
  • FIGURE 9 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 10 CLINICAL CHEMISTRY SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 11 DIAGNOSTIC PRODUCTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 12 CEREBROSPINAL FLUID TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 13 CLINICAL DIAGNOSTICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 14 HOSPITAL LABORATORIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 16 BODY FLUID ANALYSIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17 BODY FLUID ANALYSIS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 18 BODY FLUID ANALYSIS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 19 BODY FLUID ANALYSIS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 20 BODY FLUID ANALYSIS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 21 BODY FLUID ANALYSIS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 22 NUMBER OF DEALS & FUNDING ACTIVITIES IN BODY FLUID ANALYSIS MARKET
  • FIGURE 23 PATENT ANALYSIS FOR BODY FLUID ANALYSIS, JANUARY 2016-DECEMBER 2025
  • FIGURE 24 MARKET POTENTIAL OF AI IN BODY FLUID ANALYSIS MARKET
  • FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
  • FIGURE 26 KEY BUYING CRITERIA, BY PRODUCT
  • FIGURE 27 NORTH AMERICA: BODY FLUID ANALYSIS MARKET SNAPSHOT
  • FIGURE 28 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET SNAPSHOT
  • FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN BODY FLUID ANALYSIS MARKET, 2023-2025 (USD MILLION)
  • FIGURE 30 BODY FLUID ANALYSIS MARKET SHARE ANALYSIS, 2025 (GLOBAL)
  • FIGURE 31 US BODY FLUID ANALYSIS MARKET SHARE ANALYSIS, 2025 (US)
  • FIGURE 32 BODY FLUID ANALYSIS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 33 BODY FLUID ANALYSIS MARKET: COMPANY FOOTPRINT
  • FIGURE 34 BODY FLUID ANALYSIS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 35 EV/EBITDA OF KEY VENDORS
  • FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 37 BODY FLUID ANALYSIS MARKET: PRODUCT COMPARISON FOR BODY FLUID ANALYSIS
  • FIGURE 38 DANAHER: COMPANY SNAPSHOT (2025)
  • FIGURE 39 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
  • FIGURE 40 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2025)
  • FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2025)
  • FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 43 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025)
  • FIGURE 44 BIOMERIEUX: COMPANY SNAPSHOT (2025)
  • FIGURE 45 SYSMEX CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 46 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2025)
  • FIGURE 47 QIAGEN: COMPANY SNAPSHOT (2025)
  • FIGURE 48 REVVITY: COMPANY SNAPSHOT (2025)
  • FIGURE 49 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025)
  • FIGURE 50 HORIBA, LTD.: COMPANY SNAPSHOT (2025)
  • FIGURE 51 RESEARCH DESIGN
  • FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 53 TOP-DOWN APPROACH
  • FIGURE 54 DATA TRIANGULATION